<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38128296</PMID><DateCompleted><Year>2024</Year><Month>01</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1464-3391</ISSN><JournalIssue CitedMedium="Internet"><Volume>98</Volume><PubDate><Year>2024</Year><Month>Jan</Month><Day>15</Day></PubDate></JournalIssue><Title>Bioorganic &amp; medicinal chemistry</Title><ISOAbbreviation>Bioorg Med Chem</ISOAbbreviation></Journal><ArticleTitle>Elongation of N<sup>6</sup>-benzyladenosine scaffold via Pd-catalyzed C-C bond formation leads to derivatives with antiflaviviral activity.</ArticleTitle><Pagination><StartPage>117552</StartPage><MedlinePgn>117552</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bmc.2023.117552</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0968-0896(23)00400-5</ELocationID><Abstract><AbstractText>Decoration of nucleoside analogues with lipophilic groups often leads to compounds with improved antiviral activity. For example, N<sup>6</sup>-benzyladenosine derivatives containing elongated lipophilic substituents in the benzyl core efficiently inhibit reproduction of tick-borne encephalitis virus (TBEV), while N<sup>6</sup>-benzyladenosine itself potently inhibits reproduction of human enterovirus A71 (EV-A71). We have extended a series of N<sup>6</sup>-benzyladenosine analogues using effective synthetic methods of CC bond formation based on Pd-catalyzed cross-coupling reactions (Sonogashira and Suzuki) in order to study the influence of bulky lipophilic substituents in the N<sup>6</sup> position of adenosine on the antiviral activity against flaviviruses, such as TBEV, yellow fever virus (YFV) and West Nile virus (WNV), as well as a panel of enteroviruses including EV-A71, Echovirus 30 (E30), and poliovirus type 2 (PV2). Reproduction of tested flaviviruses appeared to be inhibited by the micromolar concentrations of the compounds, while cytotoxicity in most cases was beyond the detection limit. Time-of-addition studies demonstrated that the hit compounds inhibited the stage of viral RNA synthesis, but not the stages of the viral entry or protein translation. As a result, several new promising antiflaviviral leads have been identified. On the other hand, none of the synthesized compounds inhibited enterovirus reproduction, indicating a possibility of involvement of flavivirus-specific pathways in their mechanism of action.</AbstractText><CopyrightInformation>Copyright © 2023 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zenchenko</LastName><ForeName>Anastasia A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Engelhardt Institute of Molecular Biology, Moscow 119991, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drenichev</LastName><ForeName>Mikhail S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Engelhardt Institute of Molecular Biology, Moscow 119991, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khvatov</LastName><ForeName>Evgeny V</ForeName><Initials>EV</Initials><AffiliationInfo><Affiliation>FSASI "Chumakov FSC R&amp;D IBP RAS" (Institute of Poliomyelitis), Moscow 108819, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uvarova</LastName><ForeName>Victoria I</ForeName><Initials>VI</Initials><AffiliationInfo><Affiliation>FSASI "Chumakov FSC R&amp;D IBP RAS" (Institute of Poliomyelitis), Moscow 108819, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goryashchenko</LastName><ForeName>Alexander S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>FSASI "Chumakov FSC R&amp;D IBP RAS" (Institute of Poliomyelitis), Moscow 108819, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frolenko</LastName><ForeName>Vasilisa S</ForeName><Initials>VS</Initials><AffiliationInfo><Affiliation>FSASI "Chumakov FSC R&amp;D IBP RAS" (Institute of Poliomyelitis), Moscow 108819, Russia; Sechenov First Moscow State Medical University, Moscow 119991, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karpova</LastName><ForeName>Evgenia V</ForeName><Initials>EV</Initials><AffiliationInfo><Affiliation>FSASI "Chumakov FSC R&amp;D IBP RAS" (Institute of Poliomyelitis), Moscow 108819, Russia; Sechenov First Moscow State Medical University, Moscow 119991, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kozlovskaya</LastName><ForeName>Liubov I</ForeName><Initials>LI</Initials><AffiliationInfo><Affiliation>FSASI "Chumakov FSC R&amp;D IBP RAS" (Institute of Poliomyelitis), Moscow 108819, Russia; Sechenov First Moscow State Medical University, Moscow 119991, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osolodkin</LastName><ForeName>Dmitry I</ForeName><Initials>DI</Initials><AffiliationInfo><Affiliation>FSASI "Chumakov FSC R&amp;D IBP RAS" (Institute of Poliomyelitis), Moscow 108819, Russia; Sechenov First Moscow State Medical University, Moscow 119991, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishmukhametov</LastName><ForeName>Aydar A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>FSASI "Chumakov FSC R&amp;D IBP RAS" (Institute of Poliomyelitis), Moscow 108819, Russia; Sechenov First Moscow State Medical University, Moscow 119991, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mikhailov</LastName><ForeName>Sergey N</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>Engelhardt Institute of Molecular Biology, Moscow 119991, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oslovsky</LastName><ForeName>Vladimir E</ForeName><Initials>VE</Initials><AffiliationInfo><Affiliation>Engelhardt Institute of Molecular Biology, Moscow 119991, Russia. Electronic address: vladimiroslovsky@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>12</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Bioorg Med Chem</MedlineTA><NlmUniqueID>9413298</NlmUniqueID><ISSNLinking>0968-0896</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>5TWQ1V240M</RegistryNumber><NameOfSubstance UI="D010165">Palladium</NameOfSubstance></Chemical><Chemical><RegistryNumber>4294-16-0</RegistryNumber><NameOfSubstance UI="C017061">N(6)-benzyladenosine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>K72T3FS567</RegistryNumber><NameOfSubstance UI="D000241">Adenosine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010165" MajorTopicYN="N">Palladium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014902" MajorTopicYN="Y">West Nile virus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004669" MajorTopicYN="Y">Encephalitis Viruses, Tick-Borne</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000241" MajorTopicYN="N">Adenosine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiviral activity</Keyword><Keyword MajorTopicYN="N">N(6)-benzyladenosine</Keyword><Keyword MajorTopicYN="N">Nucleoside analogues</Keyword><Keyword MajorTopicYN="N">Tick‐borne encephalitis virus</Keyword><Keyword MajorTopicYN="N">West Nile virus</Keyword><Keyword MajorTopicYN="N">Yellow fever virus</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>12</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>12</Month><Day>22</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>12</Month><Day>21</Day><Hour>18</Hour><Minute>7</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38128296</ArticleId><ArticleId IdType="doi">10.1016/j.bmc.2023.117552</ArticleId><ArticleId IdType="pii">S0968-0896(23)00400-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle>